Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases.
FAIL · Does not pass the screen
6.10 USD
Price as of 28 Oct 2026Daily close, not a live quote
Screened 2026-10-28 · the tape above runs as of 04:03 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
Price6.10 USD at the 28 Oct 2026 close
Ethical screenDoes not pass
OptionsOpen interest leans to puts (put/call 272.33)
Last reviewed28 Oct 2026 (2 days ago)
A summary of the dated readings below, not a live quote and not advice.
PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
What this means: price 6.10 against the desk's fair-value range, base estimate 12.20, over the last year.
Positioning no disclosures inside 60 days, left as found
Options put/call open interest 272.33, read 2026-10-23
Ethical does not pass the values gate
Price6.10 USD
Fair value12.20
Ethical score70.0/100
Our investment reviews on this name
2026-09-24Read Markdown8.15-25.2% to today ✓Accumulation gives way to Markdown after an 11% slide in 12 weeks
2026-07-02Read Accumulation9.15-33.3% to today First review on file: Accumulation
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Anteris Technologies Global Corp. holds its Markdown at $6.10. Consolidating, no directional conviction, held for 139 days.
As held on the ledger · 2026-10-28
Phase
Markdown · caution
Quantitative state
Consolidating, no directional conviction, held for 139 days
Price at the screen
$6.10
Valuation
N/A trailing · -8.62 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.73
The Workings
Five Screens, Shown in Full
Does not pass. Accounts receivable
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
5.53%
Below 33%
Interest-bearing debt is just 5.5% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
70.21%
Below 49%
Money owed to the company is 70.2% of assets, above the 49% limit.
Fail
Revenue purity
37.06%
Below 5%
37.1% of revenue comes from non-compliant sources, over the 5% line.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Anteris Technologies Global's business is fine, but its receivables are about 70% of its assets, well over the ~49% line, so it does not pass on the financial screens.
Read as at 2026-10-29. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when AVR's ethical verdict changes
Today AVR does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
Fair value range in USD, drawn from the 2026-10-28 screen. The gold marker is the market price at the same screen. A 100.0% margin of safety to the base estimate.
Third-party analyst targets: 3 covering, consensus None. The average target sits +146% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-28 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; its business and earnings are exposed to Australia and to currency swings.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
AVR trades on Nasdaq (the company is based in Australia). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-24Markdown$6.36-6.1%Entry 9
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 6.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 3% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 76%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (4 analysts) rates it strong buy, with a mean price target of $16. Insiders have been net buyers over the past quarter.
2026-10-13Markdown$6.77-16.9%Entry 8
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 16.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 65% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 76%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (4 analysts) rates it strong buy, with a mean price target of $16. Insiders have been net buyers over the past quarter.
2026-10-02Markdown$8.15+0.0%Entry 7
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A. Technically it is holding around 65% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 76%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (4 analysts) rates it strong buy, with a mean price target of $16.
2026-09-24Markdown · changed$8.15-3.6%Entry 6
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 3.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A. Technically it is holding around 65% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 76%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (4 analysts) rates it strong buy, with a mean price target of $16.
2026-08-22Accumulation$8.45+0.0%Entry 5
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A. Technically it is holding around 65% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 76%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (4 analysts) rates it strong buy, with a mean price target of $16.
2026-07-22Accumulation$8.45-7.7%Entry 4
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 7.7% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A. Technically it is holding around 65% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 76%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (4 analysts) rates it strong buy, with a mean price target of $16.
2026-07-18Accumulation$9.15+0.0%Entry 3
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A. Technically it is holding around 65% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 76%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (4 analysts) rates it strong buy, with a mean price target of $16.
2026-07-03Accumulation$9.15+0.0%Entry 2
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
2026-07-02Accumulation$9.15Entry 1
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.